The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2018
2023
2022
2021
2020
2019
2017
2016
2015
2013
All years
December 17, 2018
PharmaResearch Products Ltd use call option in Promore Pharma
November 23, 2018
Promore Pharma AB (publ) Interim report January – September 2018
November 19, 2018
Promore Pharma receives approval for Phase III study with PXL01 in India
November 9, 2018
Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma
October 23, 2018
Promore Pharma has had a successful meeting with the FDA regarding PXL01
October 1, 2018
Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
September 6, 2018
Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
September 3, 2018
Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
August 22, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
August 20, 2018
Interim report January – June 2018
August 14, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018
July 3, 2018
Promore Pharma receives approval for Phase IIb trial with LL-37
May 16, 2018
Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018
May 16, 2018
Promore Pharma AB (publ) Interim report January – March 2018
May 9, 2018
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018
May 7, 2018
Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd
April 25, 2018
Promore Pharma 2017 Annual report published
April 19, 2018
Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma
April 11, 2018
Notice of Annual General Meeting in Promore Pharma AB (publ)
April 4, 2018
Two new smart-phone based imaging products have been adopted by Promore Pharma AB
February 15, 2018
Promore Pharma Regains Rights for PXL01 Manufacturing
February 6, 2018
Year-end report 2017
February 1, 2018
Promore Pharma is granted a patent for PXL01 in the US
January 2, 2018
Promore Pharma Adjusts Plans for PXL01 in North America
